Navigation Links
Indevus Announces Management Changes
Date:6/12/2008

ions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly, and a biodegradable ureteral stent used in association with the adjunctive treatment of kidney stones.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
3. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
4. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
7. Indevus Announces Allergan as New Partner for SANCTURA Brand
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... group leader Yung-Eun Sung has announced that they ... nitrogen-doped graphenes which can be applied as high ... Yung-Eun Sung is both a group leader at ... Basic Science* (IBS) and a professor at the ... significance with regards to the development of relative ...
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
... 16 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), ... year ended November 30, 2007. All dollar amounts ... At November 30, 2007, our cash and ... at November 30, 2006. The change in,our cash ...
... 16 Bristol-Myers Squibb,Company (NYSE: BMY ) will ... 2007 on Thursday, January 31. During a 10 a.m. ... financial information and will,address inquiries from investors and analysts., ... listen to a live,webcast of the call at ...
Cached Biology Technology:Pharmaxis' Aridol Gains First Asian Approval 2Vasogen Announces 2007 Year-End Results 2Vasogen Announces 2007 Year-End Results 3Vasogen Announces 2007 Year-End Results 4Vasogen Announces 2007 Year-End Results 5Vasogen Announces 2007 Year-End Results 6Vasogen Announces 2007 Year-End Results 7Vasogen Announces 2007 Year-End Results 8Vasogen Announces 2007 Year-End Results 9Vasogen Announces 2007 Year-End Results 10Vasogen Announces 2007 Year-End Results 11
(Date:7/25/2014)... link between autism and disrupted brain development is ... disease, and is largely unknown. However, thanks to ... (SFARI), George Washington University (GW) researcher Anthony-Samuel LaMantia, ... and in-depth answers to these key questions in ... professor of pharmacology and physiology at the GW ...
(Date:7/25/2014)... research at the University of Adelaide has opened the way ... to powdery mildew. , In Australia, annual barley production is ... Powdery mildew is one of the most important diseases of ... have discovered the composition of special growths on the cell ... fungus into the leaf. , The research, by the ARC ...
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2New hope for powdery mildew resistant barley 2It takes two to court 2It takes two to court 3
... wife doesn,t feel good on the Pill. He,d like to have ... responsibility for contraception. But they want another child, so vasectomy is ... drops his electric car off for a quick charge, he pops ... minutes of ultrasound treatment, for 6 months of contraception. Sound ...
... to help assess the spread and impact of the Deepwater ... the request of U.S. disaster response agencies. As part ... instrumented research aircraft the Earth Resources-2 (ER-2) to the Gulf ... observations and conducting additional data processing to assist the National ...
... attempt to silence the biochemical conversations that disease-causing bacteria ... a study in ACS, monthly journal, Biomacromolecules , ... soak up the substances that bacteria produce and pass ... and colleagues point out that more and more disease-causing ...
Cached Biology News:No more pills: Male contraceptive takes new approach 2No more pills: Male contraceptive takes new approach 3No more pills: Male contraceptive takes new approach 4NASA deploys planes, targets satellites to aid in oil spill response 2NASA deploys planes, targets satellites to aid in oil spill response 3
RORgamma (S-14)...
... Sophions newly introduced QPatch HT is taking ... more powerful level. With its ability to generate ... HT is enabling new screening paradigms in ion ... clamping with the same high quality afforded by ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. These microarrays are available ... Microarray Service. Probe Content ... than 1500 known aptamer sequences. Add up ...
... provides a comprehensive epitope analysis service ... on Paraflo microfluidic chips for immunological ... This comprehensive service includes assistance with ... sample(s) provided by you, single or ...
Biology Products: